Burns Matteson Capital Management’s AbbVie ABBV Stock Holding History

Burns Matteson Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,328	Closed	-$125K	–	193
2025 Q4	$125K	Hold	11,328	–	–	0.04%	195
2025 Q3	$127K	Hold	11,328	–	–	0.05%	195
2025 Q2	$104K	Hold	11,328	–	–	0.05%	181
2025 Q1	$116K	Hold	11,328	–	–	0.06%	169
2024 Q4	$99.7K	Hold	11,328	–	–	0.06%	152
2024 Q3	$110K	Hold	11,328	–	–	0.06%	148
2024 Q2	$96.6K	Hold	11,328	–	–	0.06%	149
2024 Q1	$102K	Sell	11,328 -71	-0.6%	-$12.2K	0.07%	149
2023 Q4	$99.3K	Hold	11,399	–	–	0.07%	133
2023 Q3	$95.9K	Sell	11,399 -6	-0.1%	-$881	0.06%	132
2023 Q2	$88.6K	Hold	11,405	–	–	0.05%	137
2023 Q1	$103K	Sell	11,405 -4,029	-26%	-$616K	0.07%	130
2022 Q4	$755K	Buy	+15,434	New	+$2.37M	0.5%	45
2022 Q1	–	Sell	-6,359	Closed	-$861K	–	118
2021 Q4	$861K	Buy	+6,359	New	+$751K	0.58%	38
2021 Q3	–	Sell	-3,865	Closed	-$435K	–	134
2021 Q2	$435K	Buy	3,865 +1,588	+70%	+$179K	0.34%	53
2021 Q1	$246K	Buy	+2,277	New	+$244K	0.24%	71

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Burns Matteson Capital Management's ABBV Position: Q1 2026 in Review

Burns Matteson Capital Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 11,328 shares — an estimated $125K sold.

Burns Matteson Capital Management first reported a position in ABBV in Q1 2021 and held it in 16 quarters. The position peaked at $861K in Q4 2021. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Burns Matteson Capital Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Burns Matteson Capital Management sold 11,328 AbbVie shares in Q1 2026, an estimated $125K.
Burns Matteson Capital Management first reported a position in AbbVie in Q1 2021 and held it in 16 quarters.
Burns Matteson Capital Management's AbbVie position peaked at $861K in Q4 2021.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Burns Matteson Capital Management's 13F filing for Q1 2026, filed 15 May 2026.